tiprankstipranks
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
PremiumCompany AnnouncementsLenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
2M ago
Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c)
PremiumThe Fly
Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c)
2M ago
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
PremiumPress Releases
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
2M ago
Lenz Therapeutics initiated with a Buy at Citi
PremiumThe FlyLenz Therapeutics initiated with a Buy at Citi
3M ago
LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
PremiumMarket News
LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
4M ago
Lenz Therapeutics announces results from Phase 3 CLARITY study
PremiumThe Fly
Lenz Therapeutics announces results from Phase 3 CLARITY study
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100